Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy

被引:69
作者
Oseroff, AR
Shieh, S
Frawley, NP
Cheney, R
Blumenson, LE
Pivnich, EK
Bellnier, DA
机构
[1] SUNY Buffalo, Roswell Pk Canc Inst, Dept Dermatol, Buffalo, NY 14263 USA
[2] Dept Pathol, Buffalo, NY USA
[3] Photodynam Therapy Ctr, Buffalo, NY USA
[4] Biostat Consulting Serv, Buffalo, NY USA
[5] Univ Tennessee, Dept Pediat, Memphis, TN USA
[6] Univ Tennessee, Dept Ophthalmol, Memphis, TN USA
关键词
D O I
10.1001/archderm.141.1.60
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To report the use of wide-area 5-aminolevulinic acid photodynamic therapy to treat numerous basal cell carcinomas (BCCs) and basaloid follicular hamartomas (BFHs). Design: Report of cases. Setting: Roswell Park Cancer Institute. Patients: Three children with BCCs and BFHs involving 12% to 25% of their body surface areas. Interventions: Twenty percent 5-aminolevulinic acid was applied to up to 22% of the body surface for 24 hours under occlusion. A dye laser and a lamp illuminated fields up to 7 cm and 16 cm in diameter, respectively; up to 36 fields were treated per session. Main Outcome Measures: Morbidity, patient response, and light dose-photodynamic therapy response relationship and durability. Results: Morbidity was minimal, with selective phototoxicity and rapid healing. After 4 to 7 sessions, with individual areas receiving 1 to 3 treatments, the patients had 85% to 98% overall clearance and excellent cosmetic outcomes without scarring. For laser treatments, a sigmoidal light dose-response relationship predicted more than 85% initial response rates for light doses 150 J/cm(2) or more. Responses,were durable up to 6 years. Conclusion: 5-Aminolevulinic acid photodynamic therapy is safe, well tolerated, and effective for extensive areas of diffuse BCCs and BFHs and appears to be the treatment of choice in children.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 53 条
[21]   UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].
HOLFORD, NHG ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453
[22]   Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment [J].
Horn, M ;
Wolf, P ;
Wulf, HC ;
Warloe, T ;
Fritsch, C ;
Rhodes, LE ;
Kaufmann, R ;
De Rie, M ;
Legat, FJ ;
Stender, IM ;
Solér, AM ;
Wennberg, AM ;
Wong, GAE ;
Larkö, O .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (06) :1242-1249
[23]  
Karrer S, 1999, LASER SURG MED, V25, P51, DOI 10.1002/(SICI)1096-9101(1999)25:1<51::AID-LSM7>3.0.CO
[24]  
2-Y
[25]   ENDOGENOUS PROTOPORPHYRIN-IX, A CLINICALLY USEFUL PHOTOSENSITIZER FOR PHOTODYNAMIC THERAPY [J].
KENNEDY, JC ;
POTTIER, RH .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1992, 14 (04) :275-292
[26]   PHOTODYNAMIC THERAPY WITH ENDOGENOUS PROTOPORPHYRIN .9. BASIC PRINCIPLES AND PRESENT CLINICAL-EXPERIENCE [J].
KENNEDY, JC ;
POTTIER, RH ;
PROSS, DC .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1990, 6 (1-2) :143-148
[27]  
Kimonis VE, 1997, AM J MED GENET, V69, P299, DOI 10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.3.CO
[28]  
2-#
[29]   PHOTODYNAMIC THERAPY OF NONMELANOMA SKIN-CANCER WITH TOPICAL AMINOLEVULINIC ACID - A CLINICAL AND HISTOLOGIC-STUDY [J].
LUI, H ;
SALASCHE, S ;
KOLLIAS, N ;
WIMBERLY, J ;
FLOTTE, T ;
MCLEAN, D ;
ANDERSON, RR .
ARCHIVES OF DERMATOLOGY, 1995, 131 (06) :737-738
[30]   Photodynamic therapy for basal cell carcinoma: Effect of tumor thickness and duration of photosensitizer application on response [J].
Morton, CA ;
MacKie, RM ;
Whitehurst, C ;
Moore, JV ;
McColl, JH .
ARCHIVES OF DERMATOLOGY, 1998, 134 (02) :248-249